Veru Inc.VERU

Veru Inc. is a late-stage biopharma outfit chasing cardiometabolic and inflammatory diseases with a pipeline whose lead asset is enobosarm, currently wrapped in the PLATEAU Phase 2b combination trial with semaglutide. The company’s 26 July update confirms the PLATEAU study is “actively enrolling and on track for interim analysis first quarter,” language that drips with clinical promise but leaves the commercial ledger blank. (source: Veru Reports Fiscal 2026 Second Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress, https://verupharma.com/news/veru-reports-fiscal-2026-second-quarter-financial-results-and-phase-2b-plateau-clinical-trial-progress/)

Veru itself is a company with 43.1 million dollars of assets on 31 March 2026, of which 27.6 million sits in cash and equivalents, and 34.8 million in shareholders’ equity. Those are real numbers you can count on two hands, but they sit inside a clinical-stage entity that has yet to book a single dollar of product revenue. The filing shows zero revenue for the quarter ending 31 March 2026, a fact that turns the usual biotech slide deck into a polite fiction where the top line has simply disappeared. (source: VERU 10-Q, period ending 2026-03-31, https://www.sec.gov/Archives/edgar/data/863894/000143774926016557/veru20260331_10q.htm)

Operating losses are running at 7.2 million for the quarter, with a net loss of 2.7 million, while operating cash use came in at negative 15.1 million. Research and development spend was 3.1 million, capex was zero, and inventory was flat-none of which will surprise anyone who has watched a cash-burning biotech shuffle its filing trail while waiting for a drug to arrive at the pharmacy. The balance sheet’s strongest card remains the 27.6 million in cash, but the burn rate means that card won’t last forever. (source: VERU 10-Q, period ending 2026-03-31, https://www.sec.gov/Archives/edgar/data/863894/000143774926016557/veru20260331_10q.htm)

The company’s most recent SEC 8-K on 2 July 2026 disclosed a registration statement for 3,250,000 additional shares, filed under an S-8 shelf, not a buyback programme. The optics are unmistakable: the company is choosing dilution over buybacks, and the market is left to decide whether that choice reflects confidence in future equity value or resignation to the current one. (source: VERU S-8, 2026-05-13, https://www.sec.gov/Archives/edgar/data/863894/000143774926016560/veru20260506_s8.htm)

If you want a chart, the issuer’s primary evidence is the SEC filings themselves; the company’s investor-relations site hosts the press releases but does not publish a live price feed or technical chart. The natural place to start is the issuer’s own SEC company facts page, which is less a trading terminal and more a filing trail stack with an API. (source: VERU SEC companyfacts JSON, https://data.sec.gov/api/xbrl/companyfacts/CIK0000863894.json)

What remains unproven is whether any of the pipeline assets will reach the market, and whether revenue will ever appear in the top line. The PLATEAU interim read is the next concrete data point, due in the first quarter of the next fiscal year; until then, the story is still a clinical programme with a balance sheet watching the calendar. (source: Veru Reports Fiscal 2026 Second Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress, https://verupharma.com/news/veru-reports-fiscal-2026-second-quarter-financial-results-and-phase-2b-plateau-clinical-trial-progress/)